William Blair reaffirmed their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report released on Tuesday morning, RTT News reports. William Blair also issued estimates for Nektar Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings at ($0.23) EPS, Q4 2024 […]
/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March.
Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2023 On Monday, March 4, 2024, After Close Of U.S.-Based Financial Markets menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Primecap Management Co. CA trimmed its stake in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,197,983 shares of the biopharmaceutical company’s stock after selling 951,893 shares during the period. Primecap Management […]